Upregulation of ADAM-17 expression in active lesions in multiple sclerosis

J. Plumb, S. McQuaid, A. K. Cross, J. Surr, G. Haddock, R. A D Bunning, M. N. Woodroofe

    Research output: Contribution to journalArticlepeer-review

    Abstract

    ADAM-17, a disintegrin and metalloproteinase, is the major proteinase responsible for the cleavage of membrane-bound tumour necrosis factor (TNF) as well as being an active sheddase of other cytokines, cytokine receptors, growth factors and adhesion molecules. TNF is a major proinflammatory cytokine that has been identified as having a pathogenic role in inflammatory diseases within the CNS including multiple sclerosis (MS). Here we report the cellular origin and distribution of ADAM-17 expression within clinically and neuropathologically confirmed MS and normal control white matter, assessed by immunohistochemistry, western blotting and PCR. ADAM-17 expression was associated with the blood vessel endothelium, activated macrophages/microglia and parenchymal astrocytes in MS white matter. Increased levels of ADAM-17 immunoreactivity were displayed in active lesions with evidence of recent myelin breakdown. Further studies into the functional role of ADAM-17 in the pathogenesis of MS and other inflammatory conditions are required. © 2006 Edward Arnold (Publishers) Ltd.
    Original languageEnglish
    Pages (from-to)375-385
    Number of pages10
    JournalMultiple Sclerosis
    Volume12
    Issue number4
    Publication statusPublished - Aug 2006

    Keywords

    • ADAM-17
    • Adhesion molecules
    • Astrocytes
    • Endothelium
    • Multiple sclerosis
    • TACE
    • Tumour necrosis factor

    Fingerprint

    Dive into the research topics of 'Upregulation of ADAM-17 expression in active lesions in multiple sclerosis'. Together they form a unique fingerprint.

    Cite this